Deep surgical site infections following double-dose perioperative antibiotic prophylaxis in adult obese orthopedic patients

•Obesity is a risk factor associated with orthopedic surgical site infections (SSI).•Many centers apply weight- or body mass index-related antibiotic prophylaxis to reduce deep SSIs.•The clinical benefit of the double-dose adapted antibiotic prophylaxis is unknown.•This prophylactic dose-doubling fa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of infectious diseases 2021-07, Vol.108, p.537-542
Hauptverfasser: Hasler, Anita, Unterfrauner, Ines, Olthof, Maurits G.L., Jans, Peter, Betz, Michael, Achermann, Yvonne, Uçkay, Ilker
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Obesity is a risk factor associated with orthopedic surgical site infections (SSI).•Many centers apply weight- or body mass index-related antibiotic prophylaxis to reduce deep SSIs.•The clinical benefit of the double-dose adapted antibiotic prophylaxis is unknown.•This prophylactic dose-doubling failed to reduce SSIs among the obese patients in this study. Obesity is a risk factor for surgical site infections (SSI). Based on retrospective comparisons and pharmacology, many orthopedic centers have adopted weight- or body mass index (BMI)-related antibiotic prophylaxis. Double-dose prophylaxis was introduced in March 2017 for patients weighting >80 kg. The period April 2014 to March 2017 (‘before’) was compared to the period March 2017 to June 2019 (‘after’) regarding the impact on deep SSIs. A total of 9318 surgeries ‘before’ were compared to 7455 interventions ‘after’ the introduction of double-dose prophylaxis. Baseline demographic characteristics (age, sex, BMI, American Society of Anesthesiologists score, and duration of surgery) were similar. In the period ‘after’, 3088 cases (3088/16 773; 18%) received double-dose prophylaxis. Overall, 82 deep SSIs were observed (0.5%). The pathogens were resistant to the standard cefuroxime prophylaxis in 30 cases (30/82; 37%). Excluding these prophylaxis-resistant cases and all of the five hematogenous SSIs, the remaining 47 SSIs (57%) could have been prevented by the preceding prophylaxis. Double-dosing of parenteral cefuroxime from 1.5 g to 3.0 g in obese patients did not reduce deep SSIs (hazard ratio 0.7, 95% confidence interval 0.3–1.6). In the direct group comparison among obese patients >80 kg, the double-dose prophylaxis equally failed to alter the SSI risk (3088/16 726 non-infections vs 8/47 SSI despite double-dose prophylaxis; Chi-square test, P = 0.78). In this single-center before-and-after study with almost 17 000 orthopedic surgeries in adult patients, systemic doubling of the perioperative antibiotic prophylaxis in obese patients clinically failed to reduce the overall deep SSI risk.
ISSN:1201-9712
1878-3511
DOI:10.1016/j.ijid.2021.06.008